$0.99
2.85% yesterday
Nasdaq, Jun 11, 10:02 pm CET
ISIN
US67577R1023
Symbol
IRD
Sector
Industry

Ocuphire Pharma Inc Stock price

$0.99
+0.04 4.31% 1M
-0.21 17.43% 6M
-0.20 16.73% YTD
-0.72 42.22% 1Y
-8.87 89.95% 5Y
-320.61 99.69% 10Y
-6.21 86.24% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.03 2.85%
ISIN
US67577R1023
Symbol
IRD
Sector
Industry

Key metrics

Market capitalization $59.12m
Enterprise Value $17.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.27
P/S ratio (TTM) P/S ratio 4.33
P/B ratio (TTM) P/B ratio 1.88
Revenue growth (TTM) Revenue growth -28.20%
Revenue (TTM) Revenue $13.65m
EBIT (operating result TTM) EBIT $-64.30m
Free Cash Flow (TTM) Free Cash Flow $-28.85m
Cash position $41.79m
EPS (TTM) EPS $-1.72
P/E forward negative
P/S forward 3.59
EV/Sales forward 1.05
Short interest 2.05%
Show more

Is Ocuphire Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Ocuphire Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Ocuphire Pharma Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Ocuphire Pharma Inc forecast:

Buy
100%

Financial data from Ocuphire Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
14 14
28% 28%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
38% 38%
135%
- Research and Development Expense 30 30
79% 79%
220%
-64 -64
477% 477%
-471%
- Depreciation and Amortization 0.02 0.02
100% 100%
0%
EBIT (Operating Income) EBIT -64 -64
477% 477%
-471%
Net Profit -59 -59
419% 419%
-429%

In millions USD.

Don't miss a Thing! We will send you all news about Ocuphire Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocuphire Pharma Inc Stock News

Neutral
GlobeNewsWire
10 days ago
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision, a condition with no current FDA-approved therapies Safety profile consistent with previous studi...
Neutral
GlobeNewsWire
28 days ago
ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restore meaningful vision Pediatric cohort of LCA5 study ongoing with initial multi-patient data anticipated in Q3 2025 OPGx-BEST1 on track for IND filing and initiation of Phase 1/2 trial with early data expected in Q1 2026 Leading healthcare investors provide funding to deliv...
Neutral
GlobeNewsWire
about one month ago
RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other treatments for ophthalmic disorders, today announced presentations related to its IRD gene therapy programs at these upcoming scientific conferences in May.
More Ocuphire Pharma Inc News

Company Profile

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Head office United States
CEO George Magrath
Founded 2018
Website opusgtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today